ReviewViruses2022
HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons.
Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Towards elimination of viral hepatitis in the Czech Republic, Hungary, Poland and Slovakia: insights from the Viral Hepatitis Prevention Board (VHPB).Clinical and experimental hepatology · 2026Review
- Real-World Impact of a Simplified 'Test and Treat' Strategy for In-Hospital HCV Micro-Elimination.Journal of viral hepatitis · 2026Article
- Efficiency of decentralized screening for hepatitis C in different healthcare settings: retrospective study over 6 years in southeastern Spain.Translational gastroenterology and hepatology · 2026Article
- Prevalence and predictors of HCV infection among hospitalized psychiatric patients in Poland.Frontiers in psychiatry · 2026Article
- Impact of the removal of treatment barriers on the microelimination of chronic hepatitis C in Slovak prisons: experience from real-life settings.Clinical and experimental hepatology · 2025Article
- Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies.Journal of hepatology · 2025Article
- Prevalence of Hepatitis C in the Emilia-Romagna Region of Italy: Population-Wide Screening.Viruses · 2025Article
- [Analysis of the results of the Fuxing Program Action for micro-elimination of hepatitis C in Zhuhai].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets.BMC public health · 2024Article
- Article
- Changing Epidemiological Patterns of Infection and Mortality Due to Hepatitis C Virus in Poland.Journal of clinical medicine · 2023Article
- Predictors of Significant Liver Fibrosis in People with Chronic Hepatitis C Who Inject Drugs in the Czech Republic.Life (Basel, Switzerland) · 2023Article
- Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.World journal of gastroenterology · 2023Review
- Seroprevalence Trends and Molecular Epidemiology of Viral Hepatitis in Croatia.Life (Basel, Switzerland) · 2023Review
- Efficacy of a comprehensive strategy for the detection and treatment of hepatitis C infection in a population attending addiction centers.Frontiers in public health · 2023Article
- Article
- Hepatitis C Virus Epidemiology in Lithuania: Situation before Introduction of the National Screening Programme.Viruses · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 10 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2016, the WHO announced a plan to eliminate viral hepatitis as a public health threat by 2030. In this narrative review, experts from Bulgaria, Croatia, the Czech Republic, Hungary, Latvia, Lithuania, Poland and Slovakia assessed the feasibility of achieving the WHO 2030 target for HCV infections in Central Europe. They focused mainly on HCV micro-elimination in prisons, where the highest incidence of HCV infections is usually observed, and the impact of the COVID-19 pandemic on the detection and treatment of HCV infections. According to the presented estimates, almost 400,000 people remain infected with HCV in the analyzed countries. Interferon-free therapies are available ad libitum, but the number of patients treated annually in the last two years has halved compared to 2017-2019, mainly due to the COVID-19 pandemic. None of the countries analyzed had implemented a national HCV screening program or a prison screening program. The main reason is a lack of will at governmental and prison levels. None of the countries analyzed see any chance of meeting the WHO targets for removing viral hepatitis from the public threat list by 2030, unless barriers such as a lack of political will and a lack of screening programs are removed quickly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.